Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Dose-escalation Phase I Clinical Study on Evaluating the Tolerability, Pharmacokinetic Characteristics, Safety and Preliminary Efficacy of MT027 in Patients with Recurrent or Progressive High-grade Glioma

NCT06737146 is registered in ClinicalTrials.gov with Suzhou Maximum Bio-tech Co., Ltd. as lead sponsor.

NCT NCT06737146
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06737146 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Dose-escalation Phase I Clinical Study on Evaluating the Tolerability, Pharmacokinetic Characteristics, Safety and Preliminary Efficacy of MT027 in Patients with Recurrent or Progressive High-grade Glioma
Lead sponsor
Suzhou Maximum Bio-tech Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
January 1, 2025
Completion date
December 30, 2026
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high-grade glioma